European CAR T-cell Meeting, 2022


  1. Long-Term Follow-Up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (AxiCel) in Patients With Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
  2. Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma (LBCL)
  3. Prophylactic Corticosteroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 1-Year Follow-Up of ZUMA-1 Cohort 6 (C6)
  4. Long-Term (5 Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)
  5. Real-world Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-cell Lymphoma (LBCL): Subset Analysis of Patients with Asian Descent
  6. Superiority of Axicabtagene Ciloleucel (Axi-Cel) in Second-Line (2L) Large B-Cell Lymphoma (LBCL) in the Elderly
  7. Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma